- Home
- PMN vs BLRX Comparison
PMN vs BLRX Comparison
Compare PMN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- BLRX
- Stock Information
- Founded
- PMN 2004
- BLRX 2003
- Country
- PMN Canada
- BLRX Israel
- Employees
- PMN N/A
- BLRX N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- BLRX Health Care
- Exchange
- PMN Nasdaq
- BLRX Nasdaq
- Market Cap
- PMN 17.0M
- BLRX 15.3M
- IPO Year
- PMN N/A
- BLRX 2011
- Fundamental
- Price
- PMN $0.49
- BLRX $4.45
- Analyst Decision
- PMN Strong Buy
- BLRX Strong Buy
- Analyst Count
- PMN 2
- BLRX 2
- Target Price
- PMN $4.50
- BLRX $19.00
- AVG Volume (30 Days)
- PMN 42.3K
- BLRX 2.1M
- Earning Date
- PMN 08-07-2025
- BLRX 08-14-2025
- Dividend Yield
- PMN N/A
- BLRX N/A
- EPS Growth
- PMN N/A
- BLRX N/A
- EPS
- PMN N/A
- BLRX N/A
- Revenue
- PMN N/A
- BLRX $22,340,000.00
- Revenue This Year
- PMN N/A
- BLRX N/A
- Revenue Next Year
- PMN N/A
- BLRX N/A
- P/E Ratio
- PMN N/A
- BLRX N/A
- Revenue Growth
- PMN N/A
- BLRX 91.68
- 52 Week Low
- PMN $0.47
- BLRX $2.30
- 52 Week High
- PMN $2.37
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- PMN 43.83
- BLRX 50.17
- Support Level
- PMN $0.48
- BLRX $3.79
- Resistance Level
- PMN $0.53
- BLRX $4.62
- Average True Range (ATR)
- PMN 0.03
- BLRX 0.56
- MACD
- PMN 0.00
- BLRX -0.13
- Stochastic Oscillator
- PMN 21.29
- BLRX 21.79
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.